page_banner

products

Hygromycin A CAS:6379-56-2 Homomycin

short description:


  • Molecular formula: C23H29NO12
  • Molecular weight: 511.48
  • Melting point: 105-109°; mp 110-112°
  • Specific rotation: D25 -126° (c = 1 in water)
  • Acidity coefficient: 8.9(at 25℃)
  • Email: salesexecutive1@yeah.net
  • Whatsapp: +86 15630141535
  • Wickr: lilywang
  • Product Detail

    Product Tags

    Contact me:

    Email:salesexecutive1@yeah.net

    Whatsapp:+8618931626169

    Wickr:liliwang

     

    Chemical Properties:
    White powder. Weakly acidic. Freely soluble in water and alcohol. Produced by Streptomyces hygroscopicus.
    Uses:
    Hygromycin A, a neglected antibiotic, selectively kills the bacteria that cause Lyme disease. It was able to treat Lyme disease in mice without disrupting the microbiome.
    Medicine (broad-spectrum antibiotic).
    Definition ChEBI: A natural product found in Streptomyces species.

     

     

    89ca9d09fe6b446591b3025aeb640d5e

    SR 9009 is a synthetic REV-ERB agonist that regulates circadian behavior and metabolism; has potential use in the treatment of sleep disorders and metabolic diseases. It is a lead compound for a new class of cancer drugs associated with the body’s circadian clock.

    SR9009, also known as Stenabolic, is a research drug as agonist of REV-ERB.
    REV-ERB-α and REV-ERB-β, two nuclear receptors, have a critical role in regulating the expression of core clock proteins driving rhythms in activity and metabolism.
    In vitro: Both SR9009 and its analog SR9011 could dose-dependently increase the REV-ERB-dependent repressor activity assessed in HEK293 cells expressing a chimaeric Gal4 DNA binding domain: REV-ERB ligand binding domain α or β and a Gal4-responsive luciferase reporter. In addition, SR9009 was found to be able to suppress BMAL1 messenger RNA expression in HepG2 cells in a REV-ERB-α/β-dependent manner.
    In vivo: Mice were treated with a single dose of SR9009, SR9011 or vehicle at circadian time 6 (CT6 (6h after lights on) after 12 days in D/D conditions showing peak expression of Rev-erb-α. Results showed that vehicle injection caused no disruption in circadian locomotor activity. In contrast, administration of a single dose of either SR9009 or SR9011 led to the loss of locomotor activity during the subject dark phase. In addition, the normal activity returned the next circadian cycle, which was consistent with clearance of the drugs in less than 24h. 082f5120768c41d8b7d9cca71796b1d3


    https://www.chem-peptide-steroids.com/products/

    https://www.chem-peptide-steroids.com/products/



  • Previous:
  • Next:

  • Write your message here and send it to us